| __timestamp | Celldex Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 205018000 |
| Thursday, January 1, 2015 | 4011000 | 392709000 |
| Friday, January 1, 2016 | 102026000 | 299694000 |
| Sunday, January 1, 2017 | 96171000 | 397061000 |
| Monday, January 1, 2018 | 66449000 | 434100000 |
| Tuesday, January 1, 2019 | 42672000 | 782200000 |
| Wednesday, January 1, 2020 | 42534000 | 1119900000 |
| Friday, January 1, 2021 | 3068000 | 2437500000 |
| Saturday, January 1, 2022 | 1400000 | 1560400000 |
| Sunday, January 1, 2023 | 3008000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Data in motion
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Regeneron consistently outpaced Celldex, with its cost of revenue peaking at approximately $2.44 billion in 2021, a staggering 1,600% increase from 2014. In contrast, Celldex's cost of revenue saw a significant decline, dropping by nearly 97% from its 2014 peak to just $3 million in 2023. This stark contrast highlights Regeneron's robust growth and operational scale, while Celldex's leaner cost structure may reflect strategic shifts or market challenges. Understanding these dynamics offers valuable insights into the financial strategies of these biotech leaders.
Johnson & Johnson vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Incyte Corporation
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Regeneron Pharmaceuticals, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Incyte Corporation vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Grifols, S.A. vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Geron Corporation and Celldex Therapeutics, Inc.